GlobeNewswire·Sep 10, 2026, 8:05 AM ET

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals announced presentation of posters on YCANTH (VP-102) & VP-315 at the 27th Annual Las Vegas Dermatology Seminar (Sept 17–20) & Maui Derm NP+PA Fall 2026 (Sept 16–19).
Post-hoc analysis of two Phase 3 trials shows YCANTH achieves high complete clearance rates for molluscum contagiosum regardless of disease duration.
For patients with disease duration of 12 months or less, 48.9% of YCANTH-treated subjects achieved complete clearance at Day 84 compared to 16.7% for vehicle.
For patients with disease duration greater than 12 months, 58.8% of YCANTH-treated subjects achieved complete clearance compared to 5.0% for vehicle.
Median lesion count reduction was 100% with YCANTH in both duration groups, significantly outperforming vehicle reduction of 47.9% (≤12 months) & 50.9% (>12 months).
Verrica will present data on VP-315 showing potential abscopal-like effects in basal cell carcinoma, with mean tumor size reduction in 14 untreated non-target lesions & complete histological clearance in 3 of 14 lesions.
YCANTH is the first FDA-approved healthcare professional-administered treatment for molluscum contagiosum in patients aged 2 years & older.
VP-315 is an investigational oncolytic peptide immunotherapy being studied for basal cell carcinoma & other non-melanoma skin cancers.